Hereditary Hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis

Daniel V Møller*, Redi Pecini, Finn Gustafsson, Christian Hassager, Paula Hedley, Cathrine Jespersgaard, Christian Torp-Pedersen, Michael Christiansen, Lars V Køber, EchoCardiography and Heart Outcome Study (ECHOS) investigators

Abstract

Background: It is believed that hereditary hemochromatosis (HH) might play a role in cardiac disease (heart failure (HF) and ischemia). Mutations within several genes are HH-associated, the most common being the HFE gene. In a large cohort of HF patients, we sought to determine the etiological role and the prognostic significance of HFE genotypes.

Methods: We studied 667 HF patients (72.7% men) with depressed systolic function, enrolled in a multicentre trial with a follow-up period of up to 5 years. All were genotyped for the known HFE variants C282Y, H63D and S65C.

Results: The genotype and allele frequencies in the HF group were similar to the frequencies determined in the general Danish population. In multivariable analysis mortality was not predicted by C282Y-carrier status (HR 1.2, 95% CI: 0.8-1.7); H63D-carrier status (HR 1.0, 95% CI: 0.7-1.3); nor S65C-carrier status (HR 1.2, 95% CI: 0.7-2.0). We identified 27 (4.1%) homozygous or compound heterozygous carriers of HFE variants. None of these carriers had a clinical presentation suggesting hemochromatosis, but hemoglobin and ferritin levels were higher than in the rest of the cohort. Furthermore, a trend towards reduced mortality was seen in this group in univariate analyses (HR 0.4, 95% CI: 0.2-0.9, p = 0.03), but not in multivariate (HR 0.5, 95% CI: 0.2-1.2).

Conclusion: HFE genotypes do not seem to be a significant contributor to the etiology of heart failure in Denmark. HFE variants do not affect mortality in HF.
have been unable to demonstrate a clear association [13,14], whereas another, focusing on cardiomyopathies of different etiologies, found that polymorphisms in the HFE gene was associated with ischemic heart disease, but there were neither biochemical markers nor survival data available[15].

We hypothesized that HFE genotypes might play an etiological role in heart failure (HF) or that variants in HFE might modify the clinical prognosis of HF.

We explored this hypothesis in two ways. Firstly, we examined the frequency of the most common HFE polymorphisms C282Y (dbSNP rs 1800562), H63D (dbSNP rs 1799945) and S65C (dbSNP rs 1800730) in a large HF population and assessed whether the HFE genotypes C282Y/C282Y, H63D/H63D, S65C/S65C, C282Y/H63D, C282Y/S65C and H63D/S65C, causing HH, were overrepresented in HF, suggesting an etiological role. Secondly, we studied the relation between different HFE genotypes and all-cause mortality in the same population.

**Methods**

**Subjects and clinical investigations**

The study population was based on consecutive patients enrolled in the Echocardiography and Heart Outcome Study (ECHOS). ECHOS was a consecutive, prospective, double-blind, randomized, placebo-controlled Scandinavian multicentre trial. It evaluated the effect of a selective agonist of the pre-synaptic DA2-dopaminergic and α2-adrenergic receptors in patients with moderate to severe heart failure of any etiology, with New York Heart Association (NYHA) functional class II-IV. The study was neutral with respect to every preselected endpoint and biological measure[16]. To be eligible for inclusion in the study, patients were required to have a history of dyspnoea or fatigue at rest or minimal exertion, corresponding to NYHA class III-IV within the last month, requiring treatment with diuretic and had to be in NYHA class II-IV at time of randomization. Furthermore, an echocardiogram recorded at the local hospital was evaluated in a core lab prior to randomization. To be included, depressed left ventricular function corresponding to wall motion index (WMI) ≤ 1.2 (using a reverse scoring system; corresponding to a left ventricular ejection fraction ≤ 35%) had to be present[17]. Patients with acute coronary syndrome were not eligible for the study nor were patients with atrioventricular block grade II or III, clinically significant hepatic (severe cirrhosis) or renal disease (serum creatinine > 300 μmol/l), stroke within 1 month, or any illness or disorder other than heart failure which could preclude participation or severely limit survival. The local investigators classified the patients in different groups according to etiology as described previously[18]. The study conforms to the principles outlined in the Declaration of Helsinki and was approved by The Danish Board of Health as well as the Central Danish Ethics Committee. All patients gave written informed consent. There were 1000 patients randomized in the study. To ensure long term mortality status, only Danish patients with available blood samples were included in the present study, leaving 667 patients available for genotyping and follow up. Survival status was obtained from the Danish Central Person Register, where all deaths are registered within 2 weeks. The register was interrogated in July 2006, resulting in a follow up period of up to 5 years. There were no HFE genotyped patients lost to follow up.

Demographic data, NYHA class, left ventricular ejection fraction, medical history and medication at admission and at discharge as well as in-hospital complications were recorded for all randomized patients.

As the randomized study was neutral with regard to every preselected endpoint and biological measure, we made the present analysis without making any distinction between the two study treatment groups.

**Molecular genetic studies**

Genomic DNA was isolated from whole blood samples using the Maxwell®16 system (Promega, USA). The regions of HFE (Genbank accession no. NM_139011) containing C282, H63 and S65 were amplified by polymerase chain reaction (primers available upon request). Subsequently genotyping was performed by multiplex pyrosequencing using the Pyro Gold Reagents kit (Biotage, Uppsala, Sweden) and processed in a PSQ 96MA (Biotage, Uppsala, Sweden).

**Statistical analyses**

Continuous variables are summarized as medians with 5th and 95th percentiles and group comparisons performed by Wilcoxon rank sum test. Categorical variables are expressed as number and percentage of the total group and comparative analysis was done using the χ²-test. Survival and event rates were determined with the Kaplan-Meier method and comparisons between groups were performed with the log rank test. Multivariable analysis was performed using Cox proportional hazard models. All variables, except medication, were included in the multivariable analyses. In the Cox proportional hazard model, BNP was logarithmic transformed. Each HFE variant was dichotomized into carriers (hetero- and homozygote carriers) and non-carriers due to small sample size. We also evaluated the variables “any variant” and “HH-genotype”; comparing any HFE variant combination or genotypes associated to HH (C282Y/ C282Y, H63D/H63D, C282Y/H63D, C282Y/S65C and H63D/S65C) to wild type of all three variants,
respectively. Hardy-Weinberg equilibrium was tested by a \( \chi^2 \)-test with 6 degrees of freedom.

Data were analyzed using the Statistical Analysis Software (SAS version 9.1). Results were considered significant at \( p \)-value < 0.05.

**Results**

Clinical baseline characteristics of the 667 patients and their \( HFE \) variant status are summarized in table 1. The hemoglobin level in H63D carriers and the creatinine level in S65C and "any variant"-carriers were higher compared to non-carriers (\( p = 0.013; 0.025 \) and 0.04, respectively). There were a lower frequency of patients with a history of ischemic heart disease in the C282Y carrier group as well as in the “any variant” carrier group (\( p = 0.048 \) and 0.009). Otherwise there was no statistically difference with respect to any of the variables between carriers and non-carriers.

| Table 1 Clinical baseline characteristics of 667 patients hospitalized with symptomatic heart failure according to \( HFE \) genotype |
|-------------------------------------------------------------|
| **HFE variant** | **C282Y** | **H63D** | **S65C** | **Any variation** |
| Status | Carrier | non-carrier | Carrier | non-carrier | Carrier | non-carrier | Carrier | Non-carrier |
| n total | 73 | 594 | 144 | 523 | 26 | 641 | 231 | 436 |
| **Clinical data** | | | | | | | | |
| Age (years) | 72.0 (43.6-86.8) | 71.1 (49.5-85.9) | 71.3 (45.5-87.8) | 71.1 (49.5-85.3) | 72.6 (46.0-80.6) | 71.1 (48.4-86.0) | 71.5 (46.0-87.1) | 71.0 (50.0-85.9) |
| male | 55 (75) | 430 (72) | 106 (74) | 379 (72) | 18 (69) | 467 (73) | 170 (74) | 315 (72) |
| BMI (kg/m²) | 26.4 (20.3-35.1) | 26.0 (18.8-35.3) | 26.4 (18.7-34.4) | 25.9 (19.2-35.3) | 26.0 (16.7-44.7) | 26.0 (19.1-35.1) | 26.3 (19.2-35.1) | 25.8 (19.1-35.3) |
| Current smoker (%) | 21 (29) | 191 (33) | 41 (29) | 171 (33) | 11 (44) | 201 (32) | 69 (30) | 143 (33) |
| NYHA classes (%) | | | | | | | | |
| NYHA class I | 1 (1) | 21 (3) | 7 (5) | 10 (2) | 0 | 17 (3) | 8 (3) | 9 (2) |
| NYHA class II | 12 (16) | 181 (28) | 42 (29) | 122 (23) | 6 (23) | 158 (25) | 58 (25) | 106 (24) |
| NYHA class III | 47 (64) | 360 (56) | 76 (53) | 315 (58) | 15 (58) | 376 (59) | 132 (57) | 259 (60) |
| NYHA class IV | 13 (18) | 80 (12) | 19 (13) | 73 (14) | 5 (19) | 87 (14) | 34 (15) | 59 (14) |
| **Medical history** | | | | | | | | |
| CHF (%) | 62 (86) | 502 (85) | 115 (80) | 449 (86) | 23 (86) | 541 (85) | 189 (83) | 375 (86) |
| IHD (%) | 30 (41)* | 317 (53) | 65 (45) | 282 (54) | 14 (54) | 333 (52) | 104 (45)¤ | 243 (56) |
| Former AMI (%) | 23 (32) | 217 (37) | 51 (35) | 189 (36) | 9 (36) | 231 (36) | 78 (34) | 162 (37) |
| Hypertension (%) | 24 (33) | 339 (23) | 65 (25) | 192 (35) | 9 (35) | 254 (35) | 75 (35) | 164 (35) |
| COPD (%) | 14 (19) | 127 (21) | 31 (22) | 110 (21) | 8 (31) | 133 (21) | 52 (23) | 89 (20) |
| Diabetes diagnosis (%) | 13 (18) | 102 (17) | 25 (17) | 90 (17) | 7 (27) | 108 (17) | 42 (18) | 73 (17) |
| Hyperlipidaemia (%) | 22 (32) | 217 (37) | 50 (35) | 189 (37) | 9 (36) | 230 (37) | 76 (34) | 163 (38) |
| Stroke/TCI (%) | 14 (19) | 70 (12) | 16 (11) | 68 (13) | 6 (23) | 78 (12) | 34 (15) | 50 (11) |
| **Medication at discharge** | | | | | | | | |
| ACE-I (%) | 52 (72) | 474 (80) | 115 (80) | 411 (79) | 20 (77) | 506 (79) | 178 (77) | 348 (80) |
| AT-II blockers (%) | 7 (10) | 53 (9) | 13 (9) | 47 (9) | 4 (15) | 56 (9) | 24 (10) | 36 (9) |
| β-Blokage (%) | 43 (60) | 298 (50) | 70 (49) | 271 (52) | 14 (54) | 327 (51) | 121 (53) | 220 (51) |
| Diuretics (%) | 71 (99) | 578 (98) | 142 (99) | 507 (98) | 25 (96) | 624 (98) | 226 (98) | 423 (98) |
| **Paraclinical data** | | | | | | | | |
| WMI | 1.0 (0.4-1.2) | 0.9 (0.5-1.2) | 0.9 (0.5-1.2) | 0.9 (0.4-1.2) | 0.9 (0.4-1.2) | 0.9 (0.5-1.2) | 0.9 (0.4-1.2) | 0.9 (0.5-1.2) |
| Serum Ferritin (ng/ml) | 121 (31-582) | 123 (35-430) | 129 (29-430) | 122 (36-443) | 159 (42-260) | 121 (35-461) | 127 (29-417) | 121 (37-466) |
| Hemoglobin (mmol/l) | 8.8 (7.1-10.8) | 8.6 (6.7-10.4) | 8.7 (7.0-10.4)† | 8.6 (6.7-10.4) | 8.4 (6.9-9.6) | 8.6 (6.8-10.4)¶ | 8.7 (7.0-10.4)¶ | 8.5 (6.6-10.4) |
| Serum creatinin (μmol/l) | 99 (68-259) | 106 (68-203) | 108 (70-201) | 104 (67-208) | 102 (73-251)† | 105 (68-198) | 108 (68-222) | 103 (67-194) |
| BNP (pmol/L) | 1.5 (0.3-4.0) | 1.3 (0.4-4.1) | 1.3 (0.3-3.7) | 1.4 (0.4-4.1) | 1.3 (0.2-4.7) | 1.3 (0.4-4.0) | 1.3 (0.3-4.2) | 1.3 (0.4-4.0) |

**BMI** = Body Mass Index; **NYHA** = New York Heart Association functional class; **HF** = Heart Failure; **IHD** = Ischemic Heart Disease; **AMI** = Acute Myocardial Infarction; **COPD** = Chronic Obstructive Pulmonary Disease; **TCI** = Transient Cerebral Ischemia; **ACE-I** = Angiotensin Converting Enzyme-Inhibitor; **AT-II** = Angiotensin II receptor; **WMI** = Wall Motion Index; **BNP** = Brain Natriuretic Peptide; * \( p = 0.046; \) † \( p = 0.007; \) ‡ \( p = 0.025; \) § \( p = 0.002; \) ¶ \( p = 0.022. \)
Ferritin levels were normal (< 300 ng/ml) in all three patients (two men). One suffered from diabetes, while two had cerebral stroke as well as atrial fibrillation. Two of them had died, at the ages 80 and 98 years, respectively. The last one, a male age 80 years old is still alive. None of them had liver involvement or a history of skin pigmentation. There were no clinically indices supporting the HH diagnosis. However, no histological material was available to exclude iron deposition.

Table 3 summarizes the distribution of the etiologies of HF (where known) as a function of carrier or non-carrier status for each polymorphism. No association between polymorphisms and etiology was found. The relation between variant carrier status and mortality during the follow-up period (median 51 months (range: 33.6 - 64.6 months, 328 deaths (49.2%)) is also given and the S65C polymorphism is associated with significantly (p = 0.017) increased mortality. Univariate Cox proportional hazards analyses was performed to assess the impact of different HFE genotypes and their carrier-status on all-cause mortality. Only the S65C carrier status was a significant predictor of all-cause mortality (HR 1.9, 95% CI: 1.2-3.0). In multivariable Cox proportional hazard analyses the impact on all-cause mortality decreased, leaving it insignificant (HR 1.2, 95% CI: 0.7-2.0). Serum ferritin was not associated with mortality (HR 1.00, 95% CI: 0.99-1.01, p = 0.88). Significant predictors were: age (HR 1.03, 95% CI: 1.02-1.04); diabetes (HR 1.31, 95% CI: 1.00-1.75); history of stroke (HR 1.39, 95% CI: 1.01-1.91); hemoglobin-level (HR 0.88, 95% CI: 0.78-1.00); BNP (HR 1.38, 95% CI: 1.21-1.58) and chronic obstructive pulmonary disorder (HR 2.08, 95% CI: 1.60-2.70).

Discussion

The present study demonstrates in a large population hospitalized for symptomatic heart failure that the distribution of HFE polymorphisms C282Y, H65D and S65C is not dissimilar from the distribution found in the general Danish male population and that HFE genotypes is not a significant etiological factor in heart failure. None of the HFE polymorphisms carried independent prognostic information, but homozygotes or compound heterozygotes, despite having increased risk of HH, had a trend towards reduced mortality.

The hemochromatosis gene encodes HFE, a transmembrane glycoprotein which normally associates with transferrin receptor 1 (TfR1) and decreases intracellular iron and ferritin concentrations. New insights into the function of the HFE protein suggests an iron sensing function, as well as a hepcidin regulating function[20] and subsequently a pivotal role in iron homeostasis. The C282Y polymorphism disrupts the TfR1 association leading to accumulation of intracellular iron and loss of

Table 2 Distribution of HFE genotypes in 667 heart failure patients, compared to frequencies found among 6020 Danish men (Pedersen et al.[19]) showing no differences between the two studies

| Genotype | Distribution | Pedersen et al [19] |
|----------|--------------|---------------------|
|          | C282Y H63D S65C | n | expected* (%) | n | total† (%) |
| C/C H/H S/S | 436 | 434 | 65.4 | 643 | 3871 |
| Y/C D/H S/S | 61 | 61 | 9.2 | 84 | 503 |
| Y/C H/H C/S | 1 | 2 | 0.2 | 0.1/9 |
| Y/Y H/H S/S | 3 | 2 | 0.4 | 0.4/23 |
| C/C D/H S/S | 121 | 126 | 18.1 | 201/1208 |
| C/C H/H C/S | 3 | 3 | 0.4 | 0.4/27 |
| C/C D/D S/S | 12 | 9 | 1.8 | 1.8/110 |
| C/C H/H C/S | 22 | 21 | 3.3 | 3.0/183 |
| C/C H/H C/C | 0 | 0 | 0 | 0/1 |

Total 667 667 100 100/6020

* according to Hardy-Weinberg equilibrium; † of observed
iron homeostasis. How the two other polymorphisms H63D and S65C influence iron homeostasis has not yet been clarified, as they do not interrupt the TfR1 association. All three polymorphisms are associated with HH [21] with variable disease expression and penetrance. The HFE H63D polymorphism also associates with neurodegenerative disorders [22] and cerebral stroke [23] among others. We confirm the lack of association between HFE polymorphisms and IHD in our material, as well as confirming the lack of association with dilated cardiomyopathy. In addition, we found no association between the remaining etiologies to heart failure and the frequencies of the HFE polymorphisms.

Hereditary hemochromatosis has been described as a potential cause of heart failure and arrhythmias [24] and as a consequence we assessed a large heart failure population with different etiology using HFE genotyping and serum ferritin measurements. The distribution of HFE genotypes was similar to prior Danish studies [19] indicating that the role of HH appears low. The well known variable biochemical and clinical expressivity of the homozygote C282Y polymorphism can explain the discrepancy found between the frequency of C282Y homozygotes in the general population and HH [25]. The concurrence of genetic and nongenetic factors in the development of HH due to HFE polymorphisms seems present. Studies investigating modifiers of the penetrance in HFE related hemochromatosis has been conflicting in humans [26,27] despite convincing animal models [28].

To our knowledge, this is the first study that examines HFE-polymorphisms and their association with all-cause mortality in a heart failure population. Dunn et al [29] found no association between HFE polymorphisms and cardiovascular disease mortality in patients with coronary artery disease. In our study we found no association between HFE genotype and all-cause mortality irrespective of heart failure etiology including ischemic heart disease and dilated cardiomyopathy. Although we did not specify the cause of death to be cardiac or non-cardiac related as the study by nature is observational, all patients suffered from severe heart failure (NYHA class III-IV episode within a month prior to inclusion) why the main cause of death should be expected to be due to cardiovascular disorders. This fits well with prior investigations performed where cardiac mortality rates of about 50% over a 5-year period in HF-patients is seen [30]. The S65C polymorphism seemed to significantly increase mortality when tested in univariate analyses and keeping in mind the low number in this group it lost its significance when applying available covariates.

The significantly higher hemoglobin level seen in the “HH-genotype” group could explain the tendency towards decreased mortality seen in the group. It is well established that anemia in heart failure increases mortality [31] It could be speculated that the HFE genotypes predisposing HH, in our population represents a mild clinical form, not leading to organ damage but only altering hepcidin levels leading to increased erythropoiesis. Univariate analyses were significant, but due to the small sample size (27 patients) especially with the C282Y homozygous polymorphism (3 patients) we did not have enough statistical power to make any definite conclusions.

Patients with severe liver affection, i.e. biochemical suspicion of cirrhosis of the liver, were excluded from the study ruling out the presence of overt classical HH. Subsequently, we investigated the role of the various HFE genotypes. A possible source of bias could be the exclusion of patients with cerebral stroke within the last month as Ellervik et al [23] found a positive association between HFE genotypes and stroke. Thereby we could have lost patients, with a HFE genotype but without overt HH, although the amount of patients missed must be negligible, given the low frequency of HH. Furthermore, none of the excluded patients was diagnosed with HH during the follow up period assessed by the Danish Patient Register.

| Variant | Genotype | Distribution | IHD (n = 332) | Hypertension (n = 61) | DCM (n = 108) | Valve disease (n = 42) | Other (n = 57) | Unknown (n = 67) | Deceased (n = 328) (%) |
|---------|----------|--------------|--------------|---------------------|--------------|----------------------|--------------|-----------------|----------------------|
| C282Y   | Non-carrier | 594          | 303 (51.0)   | 51 (8.6)            | 93 (15.7)    | 38 (6.4)             | 49 (8.3)     | 60 (10.1)       | 290 (48.8)           |
|         | Carrier   | 73           | 29 (39.7)    | 10 (13.7)           | 15 (20.6)    | 4 (5.5)              | 8 (11.0)     | 7 (9.6)         | 38 (52.0)            |
| H63D    | Non-carrier | 523          | 268 (51.2)   | 46 (8.8)            | 80 (15.3)    | 35 (6.7)             | 39 (7.5)     | 55 (10.5)       | 263 (50.3)           |
|         | Carrier   | 144          | 64 (44.4)    | 15 (10.4)           | 28 (19.4)    | 7 (4.9)              | 18 (12.5)    | 12 (8.3)        | 65 (45.1)            |
| S65C    | Non-carrier | 641          | 318 (49.6)   | 59 (9.2)            | 104 (16.2)   | 41 (6.4)             | 54 (8.4)     | 65 (10.1)       | 309 (48.2)           |
|         | Carrier   | 26           | 14 (53.9)    | 2 (7.7)             | 4 (15.4)     | 1 (3.9)              | 3 (11.5)     | 2 (7.7)         | 19 (73.1)*           |
| Any     | Non-carrier | 436          | 230 (52.8)   | 35 (8.0)            | 65 (14.9)    | 30 (6.9)             | 30 (6.9)     | 46 (10.6)       | 210 (48.2)           |
|         | Carrier   | 231          | 102 (44.2)   | 26 (11.3)           | 43 (18.6)    | 12 (5.2)             | 27 (11.7)    | 21 (9.1)        | 118 (51.1)           |

DCM = dilated cardiomyopathy, IHD = ischemic heart disease, Other = HF due to atrial fibrillation or rare diseases, Unknown = no single disease could be assigned as the cause of HF, Deceased = deceased in the follow up period, *p = 0.019
Conclusion
In conclusion, HFE genotypes were not associated with systolic heart failure, irrespective of etiology. Secondly, HFE genotypes did not significantly affect prognosis. Therefore, it seems that performing HFE genotype screening in heart failure patients has no value, unless they display clear clinical signs of HH, including biochemical markers as elevated serum ferritin, transferrin saturation and in the future possibly also decreased hepcidin levels. Future studies should evaluate if certain HFE genotypes could have a modifying effect on heart failure mortality due to the effect on hepcidin and subsequently hemoglobin levels.

Acknowledgements
DVM was supported by The Erik and Susanna Olsens Foundation, and The P.A. Messerschmidt and Wife Foundation. The ECHOS study was supported by unrestricted grants from Chiesi Pharmaceutical Company. All ECHOS-investigators contributing to the gathering of data are acknowledged.

Author details
1Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 2Department of Clinical Biochemistry and Immunology, Statens Serum Institut, Copenhagen, Denmark. 3Department of Cardiology, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.

Authors’ contributions
DVM, MC and LK did the conception and design of the study as well as interpreting the data. CH, LK and CTP did the conception and design of the study as well as interpreting the statistical data. PH and CJ performed the molecular genetic and statistical analyses of the data. RP and FG analyzed and interpreted the statistical data. LH and CTP did the conception and design as well as writing.

Competing interests
The authors declare that they have no competing interests.

Received: 11 December 2009 Accepted: 29 July 2010

References
1. Allen KJ, Gurr LC, Constantine CC, Osborne NJ, Delatayci MB, Nicoll AJ, McAiren CE, Bahlo M, Nissel AE, Vulpé CD, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008, 358:221-230.
2. Nemet E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008, 15:169-175.
3. Nagayoshi Y, Nakayama M, Suzuki S, Hokamaki J, Shimomura H, Tsujita K, Fukuda M, Yamashita T, Nakamura Y, Sugiyama S, Fukuda M, Yamashita T, Nakamura Y, Sugiyama S, et al. A Q312X mutation in the hemjuvelin gene is associated with cardiomyopathy due to juvenile haemochromatosis. Eur J Heart Fail 2008, 10:1001-1006.
4. Pippinen A, Roetto A, Mariani R, Pelucchi S, Corenega C, Darao F, Piga A, Garozzo G, Camaschella C. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 2004, 89:359-360.
5. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003, 33:21-22.
6. Feder JN, Gniker A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13:399-408.
7. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros P, Kosty M, Venditti CP, Phatak PD, et al: Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996, 22:187-194.
8. Wiggers P, Dalhoj J, Kaer H, Ring-Larsen H, Petersen PH, Blaabjerg O, Horder M. Screening for haemochromatosis: prevalence among Danish blood donors. J Intern Med 1991, 230:265-270.
9. Milman N, Koefoed P, Pedersen P, Nielsen FC, Eiberg H. Frequency of the HFE C282Y and H63D mutations in Danish patients with clinical haemochromatosis initially diagnosed by phenotypic methods. Eur J Haematol 2003, 71:403-407.
10. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008, 88:7-15.
11. Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eddelth JH. A prospective study of coronary heart disease and the hemochromatosis (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2001, 154:739-746.
12. van der AD, Rovers MM, Grobbee DE, Marx JJ, Taal WJ, Ellenk C, Nordestgaard BG, Olynyk JK, Mills PR, Shepherd J, et al: Mutations in the HFE gene and cardiovascular disease risk: an individual patient data meta-analysis of 53,880 subjects. Circ Cardiovasc Genet 2008, 1:43-50.
13. Hannuksela J, Leppilampi M, Kaikkonen J, Taattomaa N, Heilos T, Kaartinen M, Nieminen MS, Nieminen P, Parkkala S. Hereditary hemochromatosis gene (HFE) mutations C282Y, H63D and 565C in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail 2005, 7:103-108.
14. Mahon NG, Coonar AS, Jefferis S, Coccole F, Afyoub J, Zabl H, Houlston R, Levin G, Baboonian C, McKenna WJ. Haemochromatosis gene mutations in idiopathic dilated cardiomyopathy. Heart 2000, 84:541-547.
15. Pereira AC, Cuoco MA, Mota GT, da Silva FF, Freitas HF, Bocchi EA, Soler JM, Mansur AJ, Krieger J. Hereditary hemochromatosis gene variants in patients with cardiomyopathy. Am J Cardiol 2001, 88:388-391.
16. Torp-Pedersen C, Kober L, Larsen J, Akkan D, Bruun NE, Dacorornas D, Dickstein K, Haghfelt T, Ohtin H, McMurray JJ. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail 2008, 10:89-95.
17. Kober L, Torp-Pedersen C, Larsen J, Vibeek R, Egbring H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRANsloopri Cardiac Evaluation. Eur J Heart J 1994, 15:1616-1620.
18. Pociorn R, Moller DN, Torp-Pedersen C, Hassager C, Kober L. Heart failure etiology impacts survival of patients with heart failure. Int J Cardio 2010.
19. Pedersen P, Milson GV, Milman N. Frequencies of the haemochromatosis gene (HFE) variants C282Y, H63D and 565C in 6,020 ethnic Danish men. Ann Hematol 2008, 87:735-739.
20. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006, 281:28498-28498.
21. Muta C, Raguenes O, Pecere C. HFE mutations analysis in 711 hemochromatosis probands: evidence for 565C implication in mild form of hemochromatosis. Blood 1999, 93:2502-2505.
22. Ellenk C, Birgendi H, Tybaeberg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007, 46:1071-1080.
23. Ellenk C, Tybaeberg-Hansen A, Appleyard MD, Silesen H, Boysen G, Nordestgaard BG. Hereditary hemochromatosis genotypes and risk of ischemic stroke. Neurology 2007, 68:1025-1031.
24. Demant AW, Schmiedel A, Buttner R, Lewalter T, Reichel C. Heart failure and malignant ventricular tachyarrhythmias due to hereditary hemochromatosis with iron overload cardiomyopathy. Clin Res Cardiol 2007, 96:990-903.
25. Phatak PD, Ryan DM, Cappuccio J, Oakes D, Braggins C, Provenzano K, Ebley S, Sharm RL. Prevalence and penetration of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 2002, 29:41-47.
26. Van VH, Langlois D, Deblange H, Horsmans Y, Michelsen P, Henrion J, Cartuyvels R, Billiet J, De VM, Leroux-Reoels G. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatic patients. J Hepatol 2001, 35:707-711.
27. Carter K, Bowen DJ, McCune CA, Worwood M. Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical presentation in HFE C282Y haemochromatosis: phenotype and genotype analysis. Br J Haematol 2003, 122:326-332.

28. Coppin H, Darnaud V, Kautz L, Meynard D, Aubry M, Mosser J, Martinez M, Roth MP. Gene expression profiling of Hfe-/ liver and duodenum in mouse strains with differing susceptibilities to iron loading: identification of transcriptional regulatory targets of Hfe and potential hemochromatosis modifiers. Genome Biol 2007, 8:R221.

29. Dunn T, Blankenship D, Beal N, Allen R, Schechter E, Moore W, Perveen G, Eichner J. HFE mutations in heart disease. Heart Vessels 2008, 23:348-355.

30. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.

31. Groenveld HF, Januzzi JL, Dammann K, van WJ, Hillege HL, van Veldhuizen DJ, van der MP. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008, 52:818-827.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/11/117/prepub

doi:10.1186/1471-2350-11-117
Cite this article as: Møller et al. Hereditary Hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis. BMC Medical Genetics 2010 11:117.

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit